SCHEMBL6742787

SCHEMBL6742787

Cc1ccc(CO[C@H](c2nccs2)[C@@H](N)CO)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.38
KDM4E B2RXH2 2/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
AGXT P21549 2/20 0.34
ALOX5 P09917 2/20 0.33
HPGD P15428 1/20 0.33
CYP1A2 P05177 2/20 0.32
CYP3A4 P08684 2/20 0.32
CYP2C19 P33261 2/20 0.32
CTSA P10619 2/20 0.32
CYP2C9 P11712 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
SLC6A3 Q01959 1/20 0.32
PARP10 Q53GL7 1/20 0.32
MGAM O43451 1/20 0.32
GAA P10253 1/20 0.32
SI P14410 1/20 0.32
MGAM2 Q2M2H8 1/20 0.32
NPC1 O15118 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6737939 0.73 EGFR (0.40) ALDH1A1KDM4EMEN1KMT2ACYP3A4
SCHEMBL20177203 0.71 KDM4E (0.40) ALDH1A1KDM4EMEN1KMT2ACYP1A2
SCHEMBL2355733 0.65
SCHEMBL8830241 0.63 KDM4E (0.41) KDM4EMEN1KMT2AALOX5CYP1A2
SCHEMBL10399248 0.63 AGXT (0.47) ALDH1A1KDM4EMEN1KMT2AAGXT
SCHEMBL23180521 0.63 AGXT (0.56) ALDH1A1AGXTCYP1A2PARP10NPC1
SCHEMBL5761045 0.61
SCHEMBL11057995 0.61 ALDH1A1 (0.35) ALDH1A1ALOX5CTSA
SCHEMBL30379415 0.61 SLC6A3 (0.45) KDM4ECTSASLC6A3GAANPC1
SCHEMBL8751749 0.61 CTSA (0.43) ALDH1A1CTSA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040142975-A1 Beta disubstituted metalloprotease inhibitors THE PROCTER &GAMBLE COMPANY 2004-07-22 US disclosed
US-6696456-B1 CARBOCYCLIC ACIDS AND SALTS SUCH AS (2S,3R)-3-ETHYLSULFANYL-2-(4'-FLUORO-BIPHENYL-4-SULFONYLAMINO)-3- PHENYLPROPIONIC ACID, USED AS METALLOENZYME ANTAGONISTS FOR THE PROPHYLAXIS OF DEGENERATIVE JOINT DISEASE AND AS WOUND HEALING AGENTS THE PROCTER & GAMBLE COMPANY 2004-02-24 US disclosed
EP-1224171-A1 BETA DISUBSTITUTED METALLOPROTEASE INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 2002-07-24 EP disclosed
WO-2001027084-A1 BETA DISUBSTITUTED METALLOPROTEASE INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 2001-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142975-A1 Beta disubstituted metalloprotease inhibitors ADAM17, ADAM9, SI ALDH1A1 317/4885KDM4E 947/4885MEN1 1269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.